Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Clearmind Medicine Inc. - Common Shares
(NQ:
CMND
)
3.580
+3.580 (+1789900.00%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 29, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Clearmind Medicine Inc. - Common Shares
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Novel Combination Of Cannabis-Like Compound With Classical Psychedelics Searches IP Coverage In US
↗
February 15, 2023
Israeli-based next-gen psychedelics biotech Clearmind Medicine (NASDAQ: CMND) together with partner clinical-stage pharma company SciSparc (NASDAQ: SPRC) has filed three provisional patent applications...
Via
Benzinga
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US
February 15, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US
February 15, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit Sponsored by Greenberg Traurig Tel Aviv
February 14, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
February 08, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
EXCLUSIVE: Next-Generation Psychedelics, MEAI - The Road Ahead
↗
February 01, 2023
(Part four of a four-part series) See previous parts of the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction
Via
Benzinga
Israeli Biotech Develops Ketamine Analogue To Treat Major Depression With Promising Results
↗
January 31, 2023
Israeli-based psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) and partners Bar-Ilan University and Professor Gal Yadid from the Gonda Multidisciplinary Brain Research Center have obtained...
Via
Benzinga
Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound
January 31, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
↗
January 25, 2023
Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First?
Via
Benzinga
Hebrew University' Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023
January 25, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
↗
January 25, 2023
It's time to start off the day with an overview of the biggest pre-market stock movers traders need to know about on Wednesday!
Via
InvestorPlace
EXCLUSIVE: Next-Generation Psychedelics, MEAI - What And When
↗
January 24, 2023
(Part three of a four-part series) See previous parts of the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction
Via
Benzinga
EXCLUSIVE: Next-Generation Psychedelics, MEAI - How And Why, An Israeli Scientist Explains
↗
January 23, 2023
(This is part two of a four-part series) Check out part one in the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction
Via
Benzinga
Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction
↗
January 20, 2023
(Part one of a four-part series) Increasing evidence of psychedelics’ potential for benefiting both mental and physical health conditions are moving biotech companies and scientists in the sector to...
Via
Benzinga
Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects
↗
January 19, 2023
Psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) has successfully completed two drug discovery projects with leading scientists at the Hebrew University of Jerusalem.
Via
Benzinga
Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum
January 19, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Envisioning A Cocaine-Addiction Treatment: This Next-Gen Psychedelic Shows Positive Results
↗
January 18, 2023
Israel-based psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) shared additional positive results on the impact of the MEAI molecule in the natural reward process in an in-vivo preclinical...
Via
Benzinga
Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment
January 17, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial
January 10, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
This Original Psychedelic-Based Obesity Treatment Set To First-In-Human Trials
↗
January 06, 2023
Psychedelics biopharma company Clearmind Medicine Inc. (NASDAQ: CMND) and clinical-stage firm SciSparc Ltd.
Via
Benzinga
Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial
January 05, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Israel-Based Clearmind Medicine Inc. CEO Discusses the Potential of Psychedelics for Addiction Treatment in Audio Interview with SmallCapVoice.com
January 04, 2023
Via
ACCESSWIRE
What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways
↗
January 03, 2023
What a year for psychedelics!
Via
Benzinga
Clearmind Medicine Inc.’s Psychedelic-Based Therapeutics Are Revolutionary To The Pharmaceutical Sector; Treating AUD In The Crosshairs ($CMND)
January 03, 2023
Via
AB Newswire
Topics
Intellectual Property
Clearmind Medicine Inc. Positions To Deliver A First-To-Market Psychedelic-Based Treatment For AUD ($CMND)
December 29, 2022
Via
AB Newswire
Topics
Intellectual Property
Clearmind Medicine Announces Shareholders Meeting Results
December 29, 2022
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder
December 28, 2022
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Inc. Scores Milestone Patent Issuance To Expedite And Protect Psychedelic-Based Treatment For AUD ($CMND)
December 27, 2022
Via
AB Newswire
Topics
Intellectual Property
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Clearmind Medicine Inc's CEO, Dr. Adi Zuloff-Shani
December 22, 2022
Via
ACCESSWIRE
Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute
December 21, 2022
From
Clearmind Medicine Inc.
Via
GlobeNewswire
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.